ASX · CSL.AX
CSL Limited
A$200.39+A$2.89 (+1.46%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
Loading market information…
ASX · AYA.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Artrya Limited’s quoted price sits in the lower half of its reported 52-week range, 57.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Artrya Limited’s next earnings report is currently expected on Mar 2, 2027, with estimated earnings per share of -A$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Artrya Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$0.00-100.0% vs estimate |
| Q2 2023 | Feb 21, 2023 | -A$0.08+25.09% vs estimate | A$600.00K-40.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.39+A$2.89 (+1.46%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
A$2.74+A$0.02 (+0.55%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.53% below the high.
A$196.94-A$0.15 (-0.08%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 27.82% below the high.
A$3.46+A$0.05 (+1.47%)
Cogstate Limited’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
A$0.54-A$0.02 (-2.73%)
Echo IQ Limited’s quoted price sits in the lower half of its reported 52-week range, 71.54% below the high.
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
A$0.07A$0.00 (0.0%)
Resonance Health Limited’s quoted price sits in the upper half of its reported 52-week range, 13.95% below the high.
A$0.35+A$0.02 (+4.55%)
ImExHS Limited’s quoted price sits in the lower half of its reported 52-week range, 26.6% below the high.
